Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Nymox Pharmaceutical stock price, quote, forecast and news

NYMXF
BSP733981026
A144CA

Price

0.12
Today +/-
+0.01
Today %
+8.70 %
P

Nymox Pharmaceutical stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Nymox Pharmaceutical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nymox Pharmaceutical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nymox Pharmaceutical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nymox Pharmaceutical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nymox Pharmaceutical Stock Price History

DateNymox Pharmaceutical Price
9/27/20240.12 undefined
9/25/20240.11 undefined
9/24/20240.11 undefined
9/23/20240.10 undefined
9/20/20240.11 undefined
9/19/20240.22 undefined
9/18/20240.21 undefined
9/17/20240.12 undefined
9/16/20240.15 undefined
9/13/20240.15 undefined
9/12/20240.15 undefined
9/11/20240.10 undefined
9/10/20240.14 undefined
9/9/20240.14 undefined
9/6/20240.26 undefined
9/4/20240.08 undefined
9/3/20240.05 undefined

Nymox Pharmaceutical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nymox Pharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nymox Pharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nymox Pharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nymox Pharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nymox Pharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nymox Pharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nymox Pharmaceutical’s growth potential.

Nymox Pharmaceutical Revenue, EBIT and net profit per share

DateNymox Pharmaceutical RevenueNymox Pharmaceutical EBITNymox Pharmaceutical Net Income
20220 undefined-6.65 M undefined-6.58 M undefined
20210 undefined-12.5 M undefined-12.54 M undefined
202010,000 undefined-11.72 M undefined-11.74 M undefined
2019120,000 undefined-13.33 M undefined-13.16 M undefined
2018300,000 undefined-10.64 M undefined-10.59 M undefined
2017220,000 undefined-13.24 M undefined-13.43 M undefined
2016280,000 undefined-12.87 M undefined-13.11 M undefined
20152.76 M undefined-17.66 M undefined-17.89 M undefined
20142.95 M undefined-4.72 M undefined-4.59 M undefined
20133.36 M undefined-4.88 M undefined-4.91 M undefined
20123.07 M undefined-7.59 M undefined-7.63 M undefined
20113.11 M undefined-9.63 M undefined-9.65 M undefined
2010690,000 undefined-6.51 M undefined-6.54 M undefined
2009420,000 undefined-5.13 M undefined-5.28 M undefined
2008430,000 undefined-4.63 M undefined-4.59 M undefined
2007430,000 undefined-5.73 M undefined-5.29 M undefined
2006440,000 undefined-4.83 M undefined-4.89 M undefined
2005430,000 undefined-3.54 M undefined-3.61 M undefined
2004320,000 undefined-3.62 M undefined-3.77 M undefined
2003200,000 undefined-4.3 M undefined-4.39 M undefined

Nymox Pharmaceutical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
000000000000000333220000000
-------------------33.33--------
---------------66.6766.6766.67100.00100.00-------
000000000000000222220000000
-2-3-4-3-4-3-3-4-3-3-4-5-4-5-6-9-7-4-4-17-12-13-10-13-11-12-6
----------------300.00-233.33-133.33-200.00-850.00-------
-3-3-4-3-4-3-3-4-3-3-4-5-4-5-6-9-7-4-4-17-13-13-10-13-11-12-6
--33.33-25.0033.33-25.00-33.33-25.00-33.3325.00-20.0025.0020.0050.00-22.22-42.86-325.00-23.53--23.0830.00-15.389.09-50.00
17.6518.3719.319.8920.8921.8722.6523.7724.9226.0827.6429.0129.7530.7231.9432.7133.1834.1535.2537.446.1652.6560.4768.8573.8281.9889.38
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Nymox Pharmaceutical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nymox Pharmaceutical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                                     
1.831.61.850.450.570.490.660.610.530.150.240.270.280.6713.185.921.030.30.630.372.020.857.955.243.610.831.4
10050301005010030506050304070103030180100108000000
18016063020010305030401050100130270270360590400670280010102020100
00000205070307040303040202040409040020402030300
60030100706002040000030005020001010205023016050
2.081.762.560.780.750.650.860.760.690.290.380.430.481.0813.486.331.740.941.40.692.040.978.025.333.891.031.45
500400370130270220190130301010202020102020101000030160450410170
000000000000000000000000000
0000070707070707070000000000000000
0.460.590.831.043.143.153.223.043.273.313.483.710.2200000000000000
000000000000000000000000000
400020022011020200404030300202002020202020200000
10.991.21.373.633.553.53.263.373.433.63.830.270.020.030.040.020.030.030.020.020.020.050.160.450.410.17
3.082.753.762.154.384.24.364.024.063.723.984.260.751.113.516.371.760.971.430.712.060.998.075.494.341.441.62
                                                     
6.799.6915.0516.9123.2425.828.4132.536.5539.4944.4450.1653.8557.9662.8666.0669.7176.0581.2384.9592.13108.2126.68136.55151.72165.06171.67
00.3500000.420.420.610.631.462.483.44.496.4910.4512.3612.6313.8430.6738.7235.7936.335.7731.0427.5826.99
-3.99-7.49-11.57-15.61-19.98-23.15-26.74-31.45-35.95-39.7-44.88-50.47-58.56-63.9-72.2-82.11-89.91-95.14-100.04-117.98-131.09-144.52-155.11-168.29-180.03-192.56-199.14
00000000000000000039000-720-870-590-590-5900
000000000000000000000000000
2.82.553.481.33.262.652.091.471.210.421.022.17-1.31-1.45-2.85-5.6-7.84-6.46-4.58-2.36-0.24-1.2573.442.14-0.51-0.48
0.280.20.280.490.320.30.871.221.271.71.431.081.081.492.390.640.881.381.481.841.142.020.811.631.41.271.7
00000000150210160180160240190170170120450410230210270270320290240
000000.060.060.010.030.050.030.010.010.012.622.622.622.622.55000000.0500
00035004005505006005005000000000000000000
0000000000000000000000014060230170
0.280.20.280.840.320.761.481.732.052.462.121.271.251.745.23.433.674.124.482.251.372.231.082.041.831.792.11
0000000000000000007208109300003701600
000000000000000000000000000
0000000000.050.030.020.01010.768.145.532.910.400000000
0000000000.050.030.020.01010.768.145.532.911.120.810.930000.370.160
0.280.20.280.840.320.761.481.732.052.512.151.291.261.7415.9611.579.27.035.63.062.32.231.082.042.21.952.11
3.082.753.762.143.583.413.573.23.262.933.173.46-0.050.2913.115.971.360.571.020.72.060.988.085.484.341.441.63
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nymox Pharmaceutical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nymox Pharmaceutical's financial health and stability.

Assets

Nymox Pharmaceutical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nymox Pharmaceutical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nymox Pharmaceutical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nymox Pharmaceutical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-2-3-4-3-4-3-3-4-3-3-4-5-4-5-6-9-7-4-4-17-13-13-10-13-11-12-6
000000000000000000000000000
000000000000000000000000000
0000000000000013-4-2-1-2-100-10000
0000000000010104101159634220
000000000000000000000000000
000000000000000000000000000
-2-3-4-2-3-2-2-3-3-2-4-4-3-37-10-8-6-5-3-4-6-7-7-10-9-5
000000000000000000000000000
0001,00000000000000000000000000
0001,00000000000000000000000000
000000000000000000000000000
0000000000000000001,00000000000
3350523432453443365365145876
3351422332443342355365144875
---------------------------
000000000000000000000000000
0000000000000012-7-40001-17-2-1-20
-3.46-3.64-5.27-2.81-4.24-2.94-2.84-3.89-3.64-3.1-4.59-4.88-3.51-3.57.85-10.16-8.3-6.73-5.52-3.75-4.5-6.21-7.84-7.43-10.05-9.83-5.21
000000000000000000000000000

Nymox Pharmaceutical stock margins

The Nymox Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nymox Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nymox Pharmaceutical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nymox Pharmaceutical's sales revenue. A higher gross margin percentage indicates that the Nymox Pharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nymox Pharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nymox Pharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nymox Pharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nymox Pharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nymox Pharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nymox Pharmaceutical Margin History

Nymox Pharmaceutical Gross marginNymox Pharmaceutical Profit marginNymox Pharmaceutical EBIT marginNymox Pharmaceutical Profit margin
202250 %0 %0 %
202150 %0 %0 %
202050 %-117,200 %-117,400 %
201950 %-11,108.33 %-10,966.67 %
201853.33 %-3,546.67 %-3,530 %
201736.36 %-6,018.18 %-6,104.55 %
201639.29 %-4,596.43 %-4,682.14 %
201594.2 %-639.86 %-648.19 %
201494.24 %-160 %-155.59 %
201385.42 %-145.24 %-146.13 %
201291.86 %-247.23 %-248.53 %
201190.68 %-309.65 %-310.29 %
201053.62 %-943.48 %-947.83 %
200940.48 %-1,221.43 %-1,257.14 %
200839.53 %-1,076.74 %-1,067.44 %
200744.19 %-1,332.56 %-1,230.23 %
200645.45 %-1,097.73 %-1,111.36 %
200551.16 %-823.26 %-839.53 %
200440.63 %-1,131.25 %-1,178.13 %
200340 %-2,150 %-2,195 %

Nymox Pharmaceutical Stock Sales Revenue, EBIT, Earnings per Share

The Nymox Pharmaceutical earnings per share therefore indicates how much revenue Nymox Pharmaceutical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nymox Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nymox Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nymox Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nymox Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nymox Pharmaceutical Revenue, EBIT and net profit per share

DateNymox Pharmaceutical Sales per ShareNymox Pharmaceutical EBIT per shareNymox Pharmaceutical Earnings per Share
20220 undefined-0.07 undefined-0.07 undefined
20210 undefined-0.15 undefined-0.15 undefined
20200 undefined-0.16 undefined-0.16 undefined
20190 undefined-0.19 undefined-0.19 undefined
20180 undefined-0.18 undefined-0.18 undefined
20170 undefined-0.25 undefined-0.26 undefined
20160.01 undefined-0.28 undefined-0.28 undefined
20150.07 undefined-0.47 undefined-0.48 undefined
20140.08 undefined-0.13 undefined-0.13 undefined
20130.1 undefined-0.14 undefined-0.14 undefined
20120.09 undefined-0.23 undefined-0.23 undefined
20110.1 undefined-0.29 undefined-0.3 undefined
20100.02 undefined-0.2 undefined-0.2 undefined
20090.01 undefined-0.17 undefined-0.17 undefined
20080.01 undefined-0.16 undefined-0.15 undefined
20070.01 undefined-0.2 undefined-0.18 undefined
20060.02 undefined-0.17 undefined-0.18 undefined
20050.02 undefined-0.14 undefined-0.14 undefined
20040.01 undefined-0.15 undefined-0.15 undefined
20030.01 undefined-0.18 undefined-0.18 undefined

Nymox Pharmaceutical business model

Nymox Pharmaceutical Corporation is a biopharmaceutical company specializing in the research and development of treatments for various diseases. The company was founded in the late 1980s. Nymox's business model is based on identifying more effective treatments for disorders such as prostate cancer, Alzheimer's disease, and other illnesses. The company has developed a range of proprietary technologies to find solutions for unmet medical needs. Nymox has various divisions, including urology, neurology, and infectious diseases. The urology division is one of the company's key segments, focusing on developing treatments for prostate cancer and other urological disorders. The neurology division concentrates on the treatment and prevention of Alzheimer's disease and other neurological conditions. The infectious diseases division is dedicated to developing solutions for diseases such as HIV/AIDS and hepatitis. One product offered by Nymox is a prostate cancer test based on the measurement of prostate-specific antigen (PSA). This test is used to diagnose and monitor the spread of prostate cancer. Nymox also has a treatment for prostate hypertrophy, which is used in prostate radiation therapy-induced hemorrhoids. Another product that the company is working on is NX-1207, a novel treatment for prostate cancer and prostate hypertrophy. The treatment aims to break down and destroy prostate tissue, which may help reduce symptoms and potentially prevent the progression of the disease. Nymox has also made progress in the development of treatments for Alzheimer's disease. The treatments focus on removing beta-amyloid plaques from the brain, which are responsible for the disease. However, research in the field of Alzheimer's disease is still in its early stages, and it remains to be seen how far Nymox will progress in this area. Overall, Nymox Pharmaceutical Corp has made significant strides in the development of treatments for various diseases. With a strong focus on research and development and a wide range of products and services, Nymox remains an important player in the biopharmaceutical industry. Nymox Pharmaceutical is one of the most popular companies on Eulerpool.com.

Nymox Pharmaceutical SWOT Analysis

Strengths

1. Extensive experience in the pharmaceutical industry.

2. Strong portfolio of patented products.

3. Robust research and development capabilities.

Weaknesses

1. Limited financial resources compared to larger competitors.

2. Relatively small market share in some key therapeutic areas.

3. Dependence on limited number of drug candidates in development.

Opportunities

1. Increasing demand for innovative pharmaceutical solutions.

2. Growing healthcare market, particularly in emerging economies.

3. Potential partnerships with larger pharmaceutical companies.

Threats

1. Intense competition from established pharmaceutical companies.

2. Stringent regulatory requirements for drug approval.

3. Potential disruption in supply chains due to global events.

Nymox Pharmaceutical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nymox Pharmaceutical historical P/E ratio, EBIT, and P/S ratio.

Nymox Pharmaceutical shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nymox Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nymox Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nymox Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nymox Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Nymox Pharmaceutical.

Nymox Pharmaceutical latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20230 -0.01  (0 %)2023 Q3
6/30/20230 -0.01  (0 %)2023 Q2
12/31/2013-0.05 -0.04  (24.67 %)2013 Q4
9/30/2013-0.05 -0.03  (43.5 %)2013 Q3
3/31/2013-0.05 -0.03  (34.78 %)2013 Q1
12/31/2012-0.08 -0.08  (-4.3 %)2012 Q4
9/30/2012-0.06 -0.04  (34.1 %)2012 Q3
6/30/2012-0.06 -0.05  (17.63 %)2012 Q2
3/31/2012-0.06 -0.06  (3.85 %)2012 Q1
12/31/2011-0.06 -0.06  (3.85 %)2011 Q4
1
2

Eulerpool ESG Scorecard© for the Nymox Pharmaceutical stock

Eulerpool World ESG Rating (EESG©)

44/ 100

🌱 Environment

43

👫 Social

83

🏛️ Governance

8

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Nymox Pharmaceutical list of shareholders

%
Name
Stocks
Change
Date
5.11232 % Robinson (James George)4,782,065-1,071,5154/27/2023
35.82212 % Averback (Paul)33,508,01004/19/2023
0.98888 % Lanham (Randall J Esq.)925,000100,0004/19/2023
0.03752 % First Citizens Financial Corp35,100012/31/2023
0.01069 % Cubic Asset Management, LLC10,000012/31/2023
0.00502 % BDO Wealth Advisors, LLC4,70006/30/2023
0.00042 % Morse (David S)39604/19/2023
0.00011 % Steward Wealth Management, LLC1001009/30/2023
0 % Sterling Investment Advisors, Ltd.0-2,5009/30/2022
0 % The Patriot Financial Group, LLC0-19,9003/31/2023
1
2
3
4
5
...
7

Nymox Pharmaceutical Executives and Management Board

Dr. Paul Averback73
Nymox Pharmaceutical Chairman of the Board, President, Chief Executive Officer (since 1995)
Compensation 746,749
Mr. Randall Lanham58
Nymox Pharmaceutical General Counsel, Director (since 2006)
Compensation 534,361
Mr. Richard Cutler65
Nymox Pharmaceutical Independent Director
Compensation 3,971
Prof. Dr. David Morse66
Nymox Pharmaceutical Independent Director
Compensation 3,971
Mr. James Robinson87
Nymox Pharmaceutical Independent Director
Compensation 3,971
1
2

Most common questions regarding Nymox Pharmaceutical

What values and corporate philosophy does Nymox Pharmaceutical represent?

Nymox Pharmaceutical Corp represents a value-based corporate philosophy focused on improving healthcare outcomes. The company is dedicated to developing innovative therapies and diagnostic products that address unmet medical needs. Nymox Pharmaceutical Corp emphasizes integrity, transparency, and excellence in all aspects of its operations. By leveraging its research expertise and strategic partnerships, Nymox aims to deliver cutting-edge solutions that enhance patient care. Through its commitment to advancing medical science, Nymox Pharmaceutical Corp aims to make a meaningful impact on the lives of patients and contribute to the overall well-being of society.

In which countries and regions is Nymox Pharmaceutical primarily present?

Nymox Pharmaceutical Corp is primarily present in the United States and Canada.

What significant milestones has the company Nymox Pharmaceutical achieved?

Nymox Pharmaceutical Corp has achieved significant milestones throughout its history. The company successfully developed and gained regulatory approval for its innovative drug treatments. Nymox Pharmaceutical Corp has also established strategic partnerships with leading pharmaceutical companies to expand the reach of its products. Additionally, the company has demonstrated consistent growth and expansion, reinforcing its position as a leader in the industry. Nymox Pharmaceutical Corp continues to focus on research and development, aiming to bring breakthrough therapies to market. With its strong track record, Nymox Pharmaceutical Corp is poised for continued success in the future.

What is the history and background of the company Nymox Pharmaceutical?

Nymox Pharmaceutical Corp is a renowned biopharmaceutical company with a rich history and remarkable background. Founded in 1989, Nymox has been dedicated to developing innovative diagnostic and therapeutic products for various medical conditions. The company has achieved significant milestones in the fields of urology, neurology, and infectious diseases. Nymox continues to prioritize research and development, focusing on advancing treatment options that improve patient outcomes. With its commitment to scientific excellence and breakthrough discoveries, Nymox Pharmaceutical Corp has earned a reputable position in the pharmaceutical industry, offering promising solutions to complex healthcare challenges.

Who are the main competitors of Nymox Pharmaceutical in the market?

The main competitors of Nymox Pharmaceutical Corp in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc., Merck & Co., and Eli Lilly and Company. Other notable competitors in the biopharmaceutical industry include GlaxoSmithKline, Novartis AG, and Amgen Inc. These companies compete with Nymox Pharmaceutical Corp in the development, manufacturing, and commercialization of various pharmaceutical products and treatments.

In which industries is Nymox Pharmaceutical primarily active?

Nymox Pharmaceutical Corp is primarily active in the healthcare and pharmaceutical industries.

What is the business model of Nymox Pharmaceutical?

Nymox Pharmaceutical Corp operates as a biopharmaceutical company. Its business model focuses on researching and developing innovative treatments for urological and neurodegenerative diseases. With a particular emphasis on prostate enlargement (benign prostatic hyperplasia) and Alzheimer's disease, Nymox aims to provide effective therapies and diagnostic products to improve patients' quality of life. Through extensive clinical trials and collaborations, Nymox endeavors to advance medical understanding and provide healthcare solutions worldwide.

What is the P/E ratio of Nymox Pharmaceutical 2024?

The P/E ratio cannot be calculated for Nymox Pharmaceutical at the moment.

What is the P/S ratio of Nymox Pharmaceutical 2024?

The P/S cannot be calculated for Nymox Pharmaceutical currently.

What is the AlleAktien quality score of Nymox Pharmaceutical?

The AlleAktien quality score for Nymox Pharmaceutical is 5/10.

What is the revenue of Nymox Pharmaceutical 2024?

The revenue cannot currently be calculated for Nymox Pharmaceutical.

How high is the profit of Nymox Pharmaceutical 2024?

The profit cannot currently be calculated for Nymox Pharmaceutical.

What is the business model of Nymox Pharmaceutical

Nymox Pharmaceutical Corp is a biopharmaceutical company that focuses on developing medications to treat diseases such as benign prostatic hyperplasia (BPH), Alzheimer's, HIV, and other conditions. The company operates in North America and Europe. The main product of Nymox Pharmaceutical Corp is Fexapotide Triflutate, a medication for the treatment of BPH. Fexapotide Triflutate is a biologically active peptide that is injected into the prostate and directly targets the cause of the disease. The medication has shown in clinical studies to significantly reduce BPH symptoms without causing side effects. In addition to Fexapotide Triflutate, there is also a medication called NX-1207 in phase III of clinical trials. This medication is the first of its kind to focus on reducing prostate size and symptoms in patients with BPH. In addition to medications developed for BPH, Nymox Pharmaceutical Corp also has a research pipeline for innovative medications to treat Alzheimer's and HIV. However, the products in this pipeline are still in the preclinical development phase. Nymox Pharmaceutical Corp also has another aspect of its business - licensing technologies and patents. The company owns a variety of patents related to the Fexapotide Triflutate medication and other technologies. These patents are important assets of the company and are intended to generate long-term revenue from licensing fees and other charges. Another part of Nymox Pharmaceutical Corp's business model is to seek partners to bring the Fexapotide Triflutate medication to their markets. The company currently has distribution partnerships in Europe and Asia, and is working to establish additional partnerships in other regions. Overall, Nymox Pharmaceutical Corp's business model derives its revenue from a combination of medication development and marketing, technology and patent licensing, and strategic partnerships. The company has focused on developing medications to address unmet medical needs and has earned a good reputation in the industry. The company expects that its products will contribute to better healthcare and improved quality of life for patients worldwide in the future.

What is the Nymox Pharmaceutical dividend?

Nymox Pharmaceutical pays a dividend of 0 USD distributed over payouts per year.

How often does Nymox Pharmaceutical pay dividends?

The dividend cannot currently be calculated for Nymox Pharmaceutical or the company does not pay out a dividend.

What is the Nymox Pharmaceutical ISIN?

The ISIN of Nymox Pharmaceutical is BSP733981026.

What is the Nymox Pharmaceutical WKN?

The WKN of Nymox Pharmaceutical is A144CA.

What is the Nymox Pharmaceutical ticker?

The ticker of Nymox Pharmaceutical is NYMXF.

How much dividend does Nymox Pharmaceutical pay?

Over the past 12 months, Nymox Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nymox Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Nymox Pharmaceutical?

The current dividend yield of Nymox Pharmaceutical is .

When does Nymox Pharmaceutical pay dividends?

Nymox Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nymox Pharmaceutical?

Nymox Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Nymox Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nymox Pharmaceutical located?

Nymox Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nymox Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nymox Pharmaceutical from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Nymox Pharmaceutical pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Nymox Pharmaceutical in the year 2023?

In the year 2023, Nymox Pharmaceutical distributed 0 USD as dividends.

In which currency does Nymox Pharmaceutical pay out the dividend?

The dividends of Nymox Pharmaceutical are distributed in USD.

All fundamentals about Nymox Pharmaceutical

Our stock analysis for Nymox Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nymox Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.